Investigation of the-1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification

被引:26
作者
Huang, QR
Manolios, N
机构
[1] Department of Rheumatology, Westmead Hospital, University of Sydney, Westmead
[2] Department of Rheumatology, Westmead Hospital, Westmead
关键词
allele-specific amplification; Apo-1/Fas gene; polymorphism; promoter; systemic lupus erythematosus;
D O I
10.1080/003130200104376
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Apoptosis mediated by the Apo-1/Fas and Fas ligand pathways has been implicated in many disorders, including autoimmunity and tumorigenesis. The recent identification of two polymorphisms on the 5' flanking region of the human Apo-1/Fas gene has provided useful markers for investigation of the genetic contribution of the Apo-1/Fas gene in these diseases. The Mval polymorphism at the -670 nucleotide position is frequent in the normal population, with 51% heterozygosity. The other polymorphism, a result of single nucleotide G --> A substitution at the -1377 position, does not create or delete any restriction enzyme digestion sites. In this paper, we describe a simple and rapid method for detecting the -1377 polymorphism by using allele-specific amplification (ASA). Using the ASA method, the -1377 polymorphism in a normal Caucasian population was characterised. Frequencies of 0.13 and 0.87 for allele A and G, respectively, were observed and the homozygosity of the mutant allele (A) was found in only 2% of the population. We subsequently examined the -1377 polymorphism in sporadic systemic lupus erythematosus (SLE) patients (n = 86). The results showed that both genotype distribution and allele frequencies in SLE patients were similar to that in controls, suggesting that the -1377 promoter polymorphism is unlikely to be associated with SLE susceptibility. The description of this rapid detection method and characterisation of the -1377 polymorphism are useful means for future genetic studies in diseases in which the Fas-mediated apoptosis may be involved.
引用
收藏
页码:126 / 130
页数:5
相关论文
共 17 条
  • [1] AMASAKI Y, 1995, CLIN EXP IMMUNOL, V99, P245
  • [2] PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF THE PROMOTER-SPECIFIC TRANSCRIPTION FACTOR, SPL
    BRIGGS, MR
    KADONAGA, JT
    BELL, SP
    TJIAN, R
    [J]. SCIENCE, 1986, 234 (4772) : 47 - 52
  • [3] HALIASSONS A, 1994, NUCLEIC ACIDS RES, V54, P3853
  • [4] To die or not to die - An overview of apoptosis and its role in disease
    Hetts, SW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (04): : 300 - 307
  • [5] Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene
    Huang, QR
    Morris, D
    Manolios, N
    [J]. MOLECULAR IMMUNOLOGY, 1997, 34 (8-9) : 577 - 582
  • [6] Typing the HLA-B locus by a nested primer approach and oligonucleotide hybridization
    Inamdar, A
    Sintasath, DM
    Husted, L
    Henson, V
    Ng, J
    Hartzman, RJ
    Hurley, CK
    [J]. TISSUE ANTIGENS, 1996, 47 (06): : 519 - 529
  • [7] LEITHAUSER F, 1993, LAB INVEST, V69, P415
  • [8] Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils
    Liles, WC
    Kiener, PA
    Ledbetter, JA
    Aruffo, A
    Klebanoff, SJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) : 429 - 440
  • [9] THE APOPTOSIS-1 FAS PROTEIN IN HUMAN SYSTEMIC LUPUS-ERYTHEMATOSUS
    MYSLER, E
    BINI, P
    DRAPPA, J
    RAMOS, P
    FRIEDMAN, SM
    KRAMMER, PH
    ELKON, KB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) : 1029 - 1034
  • [10] THE FAS DEATH FACTOR
    NAGATA, S
    GOLSTEIN, P
    [J]. SCIENCE, 1995, 267 (5203) : 1449 - 1456